BRAF and glioblastoma: Recently, the phase II basket trial Rare Oncology Agnostic Research (ROAR) of dabrafenib plus trametinib in patients with BRAF V600E mutation-positive recurrent or refractory HGG (including GBM), and LGG as well, has been on-going.